Re-thinking the inclusion of race in British hypertension guidance

Dipesh P. Gopal1, Grace N. Okoli1 and Mala Rao2

© The Author(s) 2021

Journal of Human Hypertension (2022) 36:333–335; https://doi.org/10.1038/s41371-021-00601-9

Last year saw the resurgence of the Black Lives Matter movement and a renewed global call for racial justice. The disproportionate impact of the covid-19 pandemic added further weight to a clear moral argument for equality within wider society. Against that background, in medicine too, long held biological assumptions about the influence of race in the diagnosis and management of illness are being evaluated, in light of expanding scientific knowledge.

Traditionally medical research typically relies on the concept of finding a single clear truth or ‘scientific’ answer. In this way researchers are seen as objective observers who have an ability to control for research biases. This is the premise of quantitative research and how race is currently seen as a proxy for understanding ethnic differences in health. However, research data and clinical guidance do not develop in a vacuum and are shaped by society and the politics of their time [1]. An alternative view to traditional medical research is that scientists are not exempt from the influence of bias, and it is impossible to correct for our biases in research. This is the premise of qualitative research. Self-ascribed race is used to provide insights into the influence of bias, and it is impossible to correct for our biases in research. This is the premise of qualitative research. Self-ascribed race is used to provide insights into the influence of bias, and it is impossible to correct for our biases in research.

WHAT DO WE KNOW ABOUT BLOOD PRESSURE AND ETHNICITY?

The current British National Institute for Health and Care Excellence guidelines [3] recommend that people who do not have Black African or Black Caribbean heritage are offered ACE inhibitors initially, in preference to calcium channel blockers or thiazide diuretics. In contrast, people who have Black African or Black Caribbean heritage are offered calcium channel blockers initially but not offered angiotensin-converting-enzyme (ACE) inhibitors. This is because all people with Black heritage are thought to be low renin responders so therefore less responsive to ACE inhibitors. However, ACE inhibitors may be offered later if calcium channel blockers are insufficient to maintain adequate blood pressure control. The inconsistency in this recommendation as well as many others was highlighted in a previous publication in this journal [4]. This correspondence was sent to the British NICE hypertension committee who considered the presented evidence but deferred guidance change (personal correspondence) until the next review, the date for this being uncertain at the current time.

The British NICE guidelines are also notable in their contrast to US [5], South African [6] and International [7] hypertension guidance, as none of these include race as a determinant of treatment decisions.

This perspective article summarises the evidence base for the guidance on the treatment of hypertension published by NICE and explains why the inclusion of race as a criterion for treatment is questionable and deserves to be reviewed as a matter of urgency.
Despite this, renin activity varies independently of blood pressure casting doubt on this theory [14, 15]. Genetic differences between members of different races are much smaller than differences between members of the same race [16, 17]. Furthermore, race is a social construct, not a biological one [12]. The classification of Black African or Caribbean lineage is self-ascribed and does not account for people with mixed heritage or people with distant Black ancestry such as grandparents or great-grandparents. People who describe themselves as white may very well have distant Black ancestry. Consequently, it becomes much more difficult for clinicians to base treatment decisions on race and who is judged to be black, especially given immigration from Asia and Africa to the UK over the last 70 years [18].

Third, the NICE UK hypertension guidelines are inconsistent, given that initial treatment is assigned on race, but subsequent second line management is not. If race is a criterion for treatment, why would it become irrelevant once initial treatment is ineffective?

Fourthly, there is no mention of race-based guidance for the use of ACE inhibitors in British NICE guidance such as in heart failure [19] or post-myocardial infarction [20] possibly as the cardiovascular protective rather than anti-hypertensive effect of prescribed medications is desired.

A factor that we must highlight is the reported increased risk of ACE inhibitor angioedema within Black people that is described in the NICE guidance evidence reviews [21]. A 2006 systematic review [22] compared the risk of ACE-inhibitor angioedema between 55252 Black and 133964 non-Black patients. The data was from 4 US cohort and randomised control trials and 1 multinational trial using US, European, Israeli, Russian and Australian populations. The incidence of ACE-inhibitor angioedema for Black people was 0.43% compared to 0.18% for non-Black people. This would give an almost 3 times higher odds ratio of angioedema for Black people, but the absolute risk is small. A 2005 US trial [23] that was not included in the meta-analysis found a similar odds ratio but higher incidence of angioedema at 1.62% in 1237 Black people compared to 11397 non-Black people. This trial was cited as evidence to use ARBs over ACE inhibitors for Black people as part of recent international hypertension guidance [7]. Interestingly it is not clear how race is defined and whether that was defined by participants or researchers. Both the meta-analysis and trial contain predominantly US data which once again may have limited applicability to British guidelines let alone international guidance. In addition, ACE-inhibitor associated angioedema is apparently not relevant in the treatment of heart failure, reinforcing the view that race as a criterion is unjustified.

Another consideration is cardiovascular outcomes which have been flagged from a recent meta-analysis [24] comparing the effect of ACE inhibitors or ARBs against other antihypertensives such as calcium channel blockers amongst Black people with hypertension with 4 to 6-year follow-up. The four US studies included in this analysis, involved 38,983 participants but since all studies did not involve all types of antihypertensives, it was not possible to include all study data in subgroup analysis. There were no significant differences in all-cause mortality or any cardiovascular outcome when comparing ACE inhibitors/ARBs to beta-blockers. However, ACE inhibitors/ARBs had 56 and 59% significantly higher risk of stroke compared to calcium channel blockers and diuretics respectively. For example, the absolute risk of stroke for Black people who were taking calcium channel blockers was 2.57% compared to 3.99% for those taking ACE inhibitors/ARBs. Once again, US data may not be applicable to the UK given differing regional and national socioeconomic inequalities [9] and perceived stress [25]. The meta-analysis concluded that the lack of measurement of blood pressure reduction in response to the analysed antihypertensives makes it hard to speculate on the cause of the higher stroke rate. Furthermore, not all the studies used multivariate regression models to adjust for known confounders such as socioeconomic inequalities. The meta-analysis compounds results for ACE inhibitors and ARBs making it hard to determine causation based on positive correlation between medication and stroke risk.

CONCLUSION

There is an urgent need to re-consider the inconsistencies in using ACE inhibitors to lower blood pressure for Black people and the rationale of assigning antihypertensives based on self-assigned race. Furthermore, there are inconsistencies in the inclusion of race in all guidelines and the reliance on US data without context for identifying short-term and long-term effects of ACE inhibitors such as angioedema or risk of stroke. There is a real concern that poorly defined self-assigned race without context, would encourage a historic perspective of racial pathology that lacks a robust scientific evidence-base to persist, and to allow persistence of existing health inequalities [26]. A more nuanced approach [27] that incorporates the fields of genetics, physiology, pharmacokinetics and social science would be more applicable to current scientific research approaches, as it would use mixed methods to integrate the complex intersection of race, ethnicity, society and medicine in the antihypertensive prescribing guidance, and indeed in all treatment guidelines in the future.

REFERENCES

1. Saini A. Superior: the return of race science. 1st ed. London: 4th estate; 2019.
2. Slevitch L. Qualitative and quantitative methodologies compared: ontological and epistemological perspectives. J Qual Assur Hospitality Tour. 2011;12:73–81.
3. NICE. Hypertension in adults: diagnosis and management: National Institute for Health and Clinical Excellence; 2019 [cited 2020 06-26]. Available from: https://www.nice.org.uk/guidance/ng136.
4. Gopal DF, Francis R. Does race belong in the hypertension guidelines? J Hum Hypertens. 2020. https://dx.doi.org/10.1038/s41371-020-00414-2.
5. Diagnosing and managing hypertension in adults: American Heart Association; 2018 [cited 2021 06 20]. Available from: https://www.heart.org/en/health-topics/high-blood-pressure/high-blood-pressure-toolkit-resources.
6. Rayner B, Jones E, Veriava Y, Seedat YK. South African Hypertension Society commentary on the American College of Cardiology/American Heart Association hypertension guidelines. Cardiovasc J Afr. 2019;30:184–7.
7. Unger T, Borghi C, Charachar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.
8. Peck RN, Smart LR, Beier R, Liwa AC, Grosskurth H, Fitzgerald DW, et al. Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. BMC Nephrol. 2013;14:201.
9. Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic Status and Hypertension: A Meta-Analysis. J Hypertens. 2015;33:221–9.
10. Dolezszar CM, McGrath JJ, Herzig AJM, Miller SB. Perceived Racial Discrimination and Hypertension: A Comprehensive Systematic Review. Health Psychol. 2014;33:20–34.
11. Sinnott SJ, Douglas JJ, Smeeth L, Williamson E, Tomlinson LA. First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care. BMJ 2020;371:m4080.
12. Mersha TB, Beck AF. The social, economic, political, and genetic value of race and ethnicity in 2020. Hum Genomics. 2020;14:37.
13. Williams SF, Nicholas SB, Sander NT. Norris KC. African Americans, hypertension and the renin angiotensin system. World J Cardiol. 2014;6:878–89.
14. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens. 2001;15:17–25.
15. Spence JD, Rayner BL. Hypertension in blacks: individualized therapy based on renin/aldosterone phenotyping. Hypertension 2018;72:263–9.
16. Witherspoon DJ, Wooding S, Rogers AR, Marchani EE, Watkins WS, Batzer MA, et al. Genetic similarities within and between human populations. Genetics. 2007;176:351–9.
17. Bhatia G, Tandon A, Patterson N, Aldrich MC, Ambrosone CB, Amos C, et al. Genome-wide scan of 29,141 African Americans finds no evidence of directional selection since admixture. Am J Hum Genet. 2014;95:437–44.
18. Smart A, Weiner K. Racialised prescriptions: enacting race/ethnicity in clinical practice guidelines and in accounts of clinical practice. Socio Health Illn. 2018;40:843–58.
FUNDING

Nil received for manuscript. DPG is an in-practice fellow supported by the Department of Health and Social Care and the National Institute for Health Research. The views expressed by DPG is those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Dipesh P. Gopal.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021